1-3 of 3
Eileen Regan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma

Lipika Goyal, Hui Zheng, Thomas A. Abrams, Rebecca Miksad, Andrea J. Bullock, Jill N. Allen, Matthew B. Yurgelun, Jeffrey W. Clark, Avinash Kambadakone, Alona Muzikansky, Michelle Knowles, Aralee Galway, Anthony J. Afflitto, Caroline F. Dinicola, Eileen Regan, Tai Hato, Emilie Mamessier, Kohei Shigeta, Rakesh K. Jain, Dan G. Duda, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 80–89.
https://doi.org/10.1158/1078-0432.CCR-18-0847
Published: 03 January 2019
View article titled, A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Open the PDF for A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, Dan G. Duda
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1557–1566.
https://doi.org/10.1158/1078-0432.CCR-12-3041
Published: 14 March 2013
View article titled, Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Open the PDF for Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View article titled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window